×
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
NASDAQ:VIVO

Meridian Bioscience (VIVO) Stock Forecast, Price & News

$27.88
+1.56 (+5.93%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$26.59
$28.03
50-Day Range
$23.75
$28.01
52-Week Range
$17.00
$28.72
Volume
279,123 shs
Average Volume
433,373 shs
Market Capitalization
$1.21 billion
P/E Ratio
19.77
Dividend Yield
N/A
Beta
0.34
30 days | 90 days | 365 days | Advanced Chart
Receive VIVO News and Ratings via Email

Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Meridian Bioscience logo

About Meridian Bioscience

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.

Headlines

Meridian Bioscience Tops Q2 EPS by 35c
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:VIVO
CUSIP
58958410
Employees
702
Year Founded
1977

Sales & Book Value

Annual Sales
$317.90 million
Cash Flow
$2.18 per share
Book Value
$8.60 per share

Profitability

Net Income
$71.41 million
Pretax Margin
23.41%

Debt

Price-To-Earnings

Miscellaneous

Free Float
42,573,000
Market Cap
$1.21 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/06/2022
Today
5/27/2022
Next Earnings (Estimated)
8/05/2022
Fiscal Year End
9/30/2022

Social Links


MarketRank

Overall MarketRank

1.38 out of 5 stars

Medical Sector

990th out of 1,424 stocks

Diagnostic Substances Industry

14th out of 27 stocks

Analyst Opinion: 1.5Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions

Is Meridian Bioscience a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Meridian Bioscience stock.
View analyst ratings for Meridian Bioscience
or view top-rated stocks.

When is Meridian Bioscience's next earnings date?

Meridian Bioscience is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022.
View our earnings forecast for Meridian Bioscience
.

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) announced its quarterly earnings data on Friday, May, 6th. The company reported $0.66 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.18. The company earned $111.23 million during the quarter, compared to analyst estimates of $99.55 million. Meridian Bioscience had a net margin of 18.34% and a trailing twelve-month return on equity of 18.79%.
View Meridian Bioscience's earnings history
.

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience issued an update on its FY 2022 earnings guidance on Monday, May, 23rd. The company provided earnings per share (EPS) guidance of $1.30-$1.40 for the period, compared to the consensus earnings per share estimate of $1.37. The company issued revenue guidance of $330.00 million-$345.00 million, compared to the consensus revenue estimate of $337.62 million.

What price target have analysts set for VIVO?

1 equities research analysts have issued 12-month target prices for Meridian Bioscience's stock. Their forecasts range from $30.00 to $30.00. On average, they expect Meridian Bioscience's stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 7.6% from the stock's current price.
View analysts' price targets for Meridian Bioscience
or view top-rated stocks among Wall Street analysts.

Who are Meridian Bioscience's key executives?
Meridian Bioscience's management team includes the following people:
  • Mr. John P. Kenny, Pres, CEO & Director (Age 53, Pay $1.51M)
  • Dr. Lourdes G. Weltzien Ph.D., Exec. VP of Life Science Bus. Unit (Age 57, Pay $665.66k)
  • Mr. Tony Serafini-Lamanna, Exec. VP of Diagnostics (Age 59, Pay $600.53k)
  • Mr. Andrew S. Kitzmiller, Exec. VP & CFO (Age 42)
  • Julie Smith, Sr. VP, Controller & Principal Accounting Officer
  • Mr. Jeff Pinkston, Director of Corp. Fin.
  • Mr. Charles Wood, VP of Corp. Strategy, Bus. Devel. & Investor Relations
  • Ms. Melissa J. McCarey, VP of Global HR
  • Ms. Susan D. Rolih, Consultant (Age 73)
  • Ms. Melissa A. Lueke, Consultant (Age 59)
What is Jack Kenny's approval rating as Meridian Bioscience's CEO?

7 employees have rated Meridian Bioscience CEO Jack Kenny on Glassdoor.com. Jack Kenny has an approval rating of 56% among Meridian Bioscience's employees. This puts Jack Kenny in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Meridian Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD), Amgen (AMGN), Alibaba Group (BABA) and Tesla (TSLA).

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

Who are Meridian Bioscience's major shareholders?

Meridian Bioscience's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.92%), Vanguard Group Inc. (10.99%), Earnest Partners LLC (8.39%), Royce & Associates LP (4.63%), Dimensional Fund Advisors LP (4.37%) and Renaissance Technologies LLC (4.21%). Company insiders that own Meridian Bioscience stock include Andrew S Kitzmiller, Anthony P Bihl III, Bryan T Baldasare, John Mccune Jr Rice, John P Kenny and Lourdes Weltzien.
View institutional ownership trends for Meridian Bioscience
.

Which institutional investors are selling Meridian Bioscience stock?

VIVO stock was sold by a variety of institutional investors in the last quarter, including LSV Asset Management, Royce & Associates LP, Massachusetts Financial Services Co. MA, Assenagon Asset Management S.A., Vanguard Group Inc., Charles Schwab Investment Management Inc., State Street Corp, and Renaissance Technologies LLC.
View insider buying and selling activity for Meridian Bioscience
or view top insider-selling stocks.

Which institutional investors are buying Meridian Bioscience stock?

VIVO stock was purchased by a variety of institutional investors in the last quarter, including Fort Washington Investment Advisors Inc. OH, Kempen Capital Management N.V., Aviva PLC, Healthcare of Ontario Pension Plan Trust Fund, Exchange Traded Concepts LLC, Quantedge Capital Pte Ltd, AlphaCrest Capital Management LLC, and NewEdge Advisors LLC. Company insiders that have bought Meridian Bioscience stock in the last two years include Andrew S Kitzmiller, and Anthony P Bihl III.
View insider buying and selling activity for Meridian Bioscience
or or view top insider-buying stocks.

How do I buy shares of Meridian Bioscience?

Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Meridian Bioscience's stock price today?

One share of VIVO stock can currently be purchased for approximately $27.88.

How much money does Meridian Bioscience make?

Meridian Bioscience has a market capitalization of $1.21 billion and generates $317.90 million in revenue each year. The company earns $71.41 million in net income (profit) each year or $1.409990 on an earnings per share basis.

How many employees does Meridian Bioscience have?

Meridian Bioscience employs 702 workers across the globe.

Does Meridian Bioscience have any subsidiaries?

The following companies are subsidiares of Meridian Bioscience: Exalenz Bioscience.

When was Meridian Bioscience founded?

Meridian Bioscience was founded in 1977.

What is Meridian Bioscience's official website?

The official website for Meridian Bioscience is www.meridianbioscience.com.

How can I contact Meridian Bioscience?

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at (513) 271-3700, via email at [email protected], or via fax at 513-271-3762.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.